All Articles

A new deal between Fushi Tech and tea giant PlayMade shows how AI and CRM are becoming critical tools for survival and growth in a competitive market.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

One California firm is rewriting the rules of law with AI and global teams, achieving massive scale. Is this the future of legal services?

Beyond the awards, the 2025 TISDC reveals Taiwan's strategy for global creative leadership and how young designers are tackling the world's biggest problems.

Bluerock Acquisition Corp. has raised $150 million. With a sector-agnostic mandate, could this new capital pool target the mining industry?

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.

The packaging giant pushed its debt wall to 2030 and stripped key covenants. We analyze the strategic brilliance and the high-stakes bargain for investors.

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

Tariff relief was a temporary fix. A powerful federal tax credit offers farmers a sustained way to fund the innovation they perform every day.

Ancient remedies meet modern AI. See how companies are using data and smart factories to transform traditional Chinese medicine into a global pharma force.

FC Supra du Québec isn't just building a team; it's building a brand. Their first signings reveal a bold, local-first strategy to win Quebec's heart.

With FDA approval and $80M in funding, ProVerum’s ProVee system aims to disrupt the BPH treatment market by prioritizing safety and patient quality of life.

A new partnership uses AI to analyze imaging, clinical, and molecular data, offering unprecedented accuracy in predicting breast cancer recurrence years later.

Shareholders approve Emeren's $102M deal to go private, a maneuver to accelerate growth in the booming solar and battery storage markets. What's next?

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

NREF's massive capital raise signals strong investor confidence. We dive into what this bold move reveals about the market and income-seeking investors.

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Serve Robotics and Uber Eats launch sidewalk robots in Alexandria, Va., testing the scalability, economics, and public acceptance of last-mile automation.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Gemini's new license to offer prediction markets signals a major regulatory shift, but it also wades into a turbulent world of ethical and legal challenges.